AstraZeneca’s Farxiga Receives the US FDA’s Fast Track Designation for Chronic Kidney Disease

 AstraZeneca’s Farxiga Receives the US FDA’s Fast Track Designation for Chronic Kidney Disease

AstraZeneca’s Farxiga Receives FDA’s Fast Track Designation for Chronic Kidney Disease

Shots:

  • The FDA’s fast track designation is based on P-III DAPA-CKD study assessing Farxiga (dapagliflozin) vs PBO on renal outcomes and CV mortality in patients with CKD with and without T2D, on the top of SOC
  • The FDA’s Fast Track designation is designed to accelerate the development and review of new therapies for the treatment of serious conditions where there is an unmet medical need
  • Farxiga (qd) is an oral SGLT2 inhibitor indicated both as a monothx. and combination therapy to improve glycemic control, with weight loss and reduction in BP, as an adjunct to diet and exercise in adults with T2D

Click here to­ read full press release/ article | Ref: Abbott | Image: Chicago Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post